<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20091012002576N20</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-07-02</date_registration>
      <primary_sponsor>Tehran University of Medical Sciences</primary_sponsor>
      <public_title>The effect of Botox on chronic pelvic pain and sexual satisfaction in women with endometriosis</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of chronic pelvic pain and sexual satisfaction in women with endometriosis in two groups with and without botulinum toxin injection</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-09-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>32</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/57209</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Random allocation rule: First, 16 letters A and 16 letters B are written on special papers that are not marked inside. Then all of them are placed in a bag and for each patient, after obtaining informed consent, a paper is removed randomly and without replacement, and based on the letter written on it, the desired intervention is performed for the patient. In addition, interventions A (botulinum toxin) or B (normal saline) are determined by a lot, Blinding description: This study is performed double-blind, the participants and the analyzer do not know the type of treatment. Patients in the control group do not know their group therapy, with using the normal saline injection in Botox-like syringes. Also, the data analyzer does not know the codes defined for the treatment groups in the SPSS file.</study_design>
      <phase>3</phase>
      <hc_freetext>Endometriosis.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: After a vaginal digital examination to identify pelvic muscles with spasms, and 20 to 30 minutes before the start of the intervention, up to 10 mg of oral diazepam is administered and lidocaine cream 4% is applied to the determined location in the vaginal mucosa. Then, a vial of 100 units of anabotulinum toxin A (Botox) is placed in 4 ccs of saline (final concentration 25 units/ml). The injection is performed by a gynecologist with experience in endometriosis using a sterile technique. When Botox is injected into one muscle, the removed needle is then inserted into the next muscle. In fact, the total dose of 100 units is divided between three to four identified areas of muscles with spasms. Intervention 2: Control group: After a vaginal digital examination to identify pelvic muscles with spasms, and 20 to 30 minutes before the start of the intervention, up to 10 mg of oral diazepam is administered and lidocaine cream 4% is applied to the determined location in the vaginal mucosa. Then, two to five ccs of normal saline are prepared. The injection is performed by a gynecologist with experience in endometriosis using a sterile technique. When normal saline is injected into one muscle, the removed needle is then inserted into the next muscle.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All data is potentially shareable after unidentified participants

When:
After manuscript published

To whom:
No limitations

Conditions:
The data is only available to the project manager, Dr. Davari-Tanha, and any analysis must be done with her opinion.

Where to obtain:
Dr. Davari-Tanha
fdavaritanha@sina.tums.ac.ir

How to obtain:
Any request for data must be sent to Dr. Davari-Tanha by email and accompanied by a written proposal confirmed by a local ethics committee.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Fatemeh Davari Tanha</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Yas hospital, Next to the sarv street , North Nejatollahi street , karim khan ave</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1597856511</zip>
        <telephone>+98 21 8831 3955</telephone>
        <email>fdavaritanha@sina.tums.ac.ir</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Fatemeh Davari Tanha</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Yas hospital, Next to the sarv street , North Nejatollahi street , karim khan ave</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1597856511</zip>
        <telephone>+98 21 8831 3955</telephone>
        <email>fdavaritanha@sina.tums.ac.ir</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age 18-50 years
Chronic pelvic pain for at least 3 months
Do not start new analgesic strategies since one month before the intervention</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>50 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>The primary cause of chronic pelvic pain is the following: infection, gastrointestinal or psychological disorder, fibromyalgia, chronic fatigue syndrome
Severe untreated cervical dysplasia
History of hysterectomy and bilateral salpingo-oophorectomy
Allergy to botulinum toxin
Pregnancy or breastfeeding
History of urinary and fecal incontinence
Known pelvic prolapse
Neuromuscular disorders such as myasthenia gravis or Lambert Aton syndrome</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>N80.9</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Endometriosis, unspecified</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: After a vaginal digital examination to identify pelvic muscles with spasms, and 20 to 30 minutes before the start of the intervention, up to 10 mg of oral diazepam is administered and lidocaine cream 4% is applied to the determined location in the vaginal mucosa. Then, a vial of 100 units of anabotulinum toxin A (Botox) is placed in 4 ccs of saline (final concentration 25 units/ml). The injection is performed by a gynecologist with experience in endometriosis using a sterile technique. When Botox is injected into one muscle, the removed needle is then inserted into the next muscle. In fact, the total dose of 100 units is divided between three to four identified areas of muscles with spasms.</i_keyword>
      <i_keyword>Control group: After a vaginal digital examination to identify pelvic muscles with spasms, and 20 to 30 minutes before the start of the intervention, up to 10 mg of oral diazepam is administered and lidocaine cream 4% is applied to the determined location in the vaginal mucosa. Then, two to five ccs of normal saline are prepared. The injection is performed by a gynecologist with experience in endometriosis using a sterile technique. When normal saline is injected into one muscle, the removed needle is then inserted into the next muscle.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Chronic pelvic pain. Timepoint: Twice, before the intervention and one month after the intervention. Method of measurement: Visual Analog Scale (VAS Ruler).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Sexual satisfaction rate. Timepoint: Once, at the end of the study. Method of measurement: Female Sexual Function Index Scoring.</sec_outcome>
      <sec_outcome>Dysmenorrhea. Timepoint: Twice, before the intervention and one month after the intervention. Method of measurement: Visual Analog Scale (VAS Ruler).</sec_outcome>
      <sec_outcome>Dyspareunia. Timepoint: Twice, before the intervention and one month after the intervention. Method of measurement: Visual Analog Scale (VAS Ruler).</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-06-14</approval_date>
        <contact_name>Ethics committee of Tehran university of medical sciences</contact_name>
        <contact_address>Tehran University of Medical Sciences,School of Medicine, Tehran Province, Tehran, Pour Sina St" to "Tehran University of Medical Sciences,School of Medicine, Tehran Province, Tehran, Pour Sina St Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
